Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LY6K drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LY6K ECD-Fc / Mutant Protein High Purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View LY6K Products |
| Gene Delivery | LY6K Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native conformation for cell-based assays. |
View LY6K Products |
| Benchmark Ab | Anti-LY6K Recombinant Antibody Sequence verified clinical/preclinical biosimilar benchmark. |
View LY6K Products |
| Validator | LY6K siRNA Set High knockdown efficiency for target specificity validation. |
View LY6K Products |
| Related Target A | LY6E Homologous member of the LY6 family; critical for off-target and selectivity screening. |
View LY6E Products |
| Related Target B | CD59 GPI-anchored LY6 family protein; widely expressed. Essential counter-screening target to avoid systemic toxicity. |
View CD59 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of LU Domain | HEK293 Expressed (Native Glycosylation) recombinant LY6K ensures correct folding of the 10-cysteine rigid LU domain. |
| Cross-Family Off-Target Binding | High Purity (>95%) LY6E and CD59 proteins available for rigorous counter-screening panels. |
| Lack of Benchmarks | Recombinant sequence-verified benchmark antibodies included for assay validation. |
| False Positives in Cell Assays | Sequence-verified siRNA sets included for functional knockdown verification. |
Live LY6K R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LY6K therapeutics is intensifying, with major players shifting focus from traditional peptide vaccines to antibody-drug conjugates (ADCs) and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific epitopes that avoid cross-reactivity with widely expressed family members like CD59, while maximizing internalization efficiency in solid tumors such as triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | CSPC Pharmaceutical Group (SYS6020), Biotech Startups | TNBC, NSCLC, Esophageal Cancer | Internalization Assay (Requires HEK293 Expressed ECD-Fc with native post-translational modifications) |
| CAR-T / Cell Therapy | Academic Institutes, Cell Therapy Biotechs | Glioblastoma, Ovarian Cancer | Conformational binding assays (Requires Lentivirus for Stable Cell Line generation to present native GPI-anchored structure) |
| Cancer Vaccine / Peptides | OncoTherapy Science | Head & Neck Cancer, Solid Tumors | MHC peptide binding validation & sequence verification |